Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.35 USD
Change Today -0.08 / -1.81%
Volume 32.8K
BIND On Other Exchanges
As of 12:09 PM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).

bind therapeutics inc (BIND) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/14 - $10.75
52 Week Low
10/5/15 - $4.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIND THERAPEUTICS INC (BIND)

Related News

No related news articles were found.

bind therapeutics inc (BIND) Related Businessweek News

No Related Businessweek News Found

bind therapeutics inc (BIND) Details

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specific pharmaceutical characteristics intended to target tumors at tissue, cellular, and molecular levels and to result in superior patient outcomes by enhancing the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The company’s lead drug candidate includes BIND-014, a prostate-specific membrane antigen (PSMA) targeted Accurin that contains docetaxel, which is in Phase II clinical trials for non-small cell lung cancer. It is also developing BIND-510, a PSMA-targeted Accurin drug candidate containing the potent microtubule inhibitor vincristine. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; AstraZeneca AB; Hoffmann-La Roche Ltd.; and Merck & Co. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

89 Employees
Last Reported Date: 03/11/15
Founded in 2006

bind therapeutics inc (BIND) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $334.9K
Chief Medical Officer
Total Annual Compensation: $84.2K
Compensation as of Fiscal Year 2014.

bind therapeutics inc (BIND) Key Developments

BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

BIND Therapeutics, Inc. announced that Pfizer Inc. exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors under the companies’ global collaboration agreement. The actively targeted Accurin is designed to impart cellular targeting capability and was engineered by BIND using one of Pfizer’s proprietary kinase inhibitors and one of BIND’s proprietary ligands. As a result of the option exercise, BIND will receive a $2.5 million option exercise fee from Pfizer. In parallel with exercising its first option, Pfizer informed BIND that it will not exercise its option for the second compound in the collaboration. Under terms of the original collaboration agreement, which was established in April 2013, Pfizer was granted options to obtain exclusive licenses to pursue development and commercialization of two Accurins that incorporate specified Pfizer small molecular targeted therapies. For the Accurin that has been selected, both companies will work together on preclinical research; Pfizer will have responsibility for development and commercialization, and BIND will conduct chemistry, manufacturing and control activities. In addition to the $2.5 million option exercise fee, BIND received an upfront payment of $4.0 million in 2013 and achieved a $1.0 million preclinical development milestone for the selected Accurin in December 2014. BIND has the potential to receive additional milestone payments for the selected Accurin of up to $86.0 million in aggregate upon the achievement of additional specified development and regulatory events under the Pfizer collaboration agreement. BIND may also receive additional milestone payments for the selected Accurin of up to $110 million in aggregate for specified commercial events as well as royalties in the low single to high single digit percentages on potential future sales of the selected Accurin, if any.

BIND Therapeutics Initiates Multicenter iNSITE 2 Trial with BIND-014 in Four Tumor Histologies

BIND Therapeutics, Inc. announced that patient dosing is underway in the iNSITE 2 trial, a global, phase 2, two-stage clinical trial of BIND-014 in patients with four tumor histologies. These diseases (cholangiocarcinoma [bile duct cancer], advanced cervical cancer, advanced bladder cancer, and advanced squamous cancer of the head and neck) each affect fewer than 200,000 patients in the U.S., making investigational drugs for these diseases candidates for orphan drug designation by the U.S. Food and Drug Administration. Stage 1 data readout for the iNSITE 2 trial is expected in the first half of 2016. The orphan tumor types that the company have chosen for iNSITE 2 are all cancers with high unmet need and limited treatment options, representing potential opportunities for rapid development. The open-label, phase 2, multi-center two-stage iNSITE 2 clinical trial is designed to determine the activity, safety and tolerability of BIND-014 and will enroll up to 160 patients. In addition, an imaging and biomarker program that can potentially inform the future clinical utility of BIND-014 is also planned.

BIND Therapeutics, Inc. Presents at 22nd Annual NewsMakers in the Biotech Industry Investment Conference, Sep-10-2015 02:00 PM

BIND Therapeutics, Inc. Presents at 22nd Annual NewsMakers in the Biotech Industry Investment Conference, Sep-10-2015 02:00 PM. Venue: Millennium Broadway Hotel & Conference Center - Breakout Room 401, 145 West 44th Street, New York, New York, United States. Speakers: Andrew Hirsch, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIND:US $4.35 USD -0.08

BIND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIND.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIND Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.9x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIND THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at